NeuroTrauma Sciences Presents Update on Neuroprotective Compounds NTS-104 and NTS-105 at the 12th Annual Traumatic Brain Injury Conference
June 7, 2022
NeuroTrauma Sciences today provided an update on the development of its lead drug candidates NTS-104 and NTS-105 in traumatic brain injury.
NeuroTrauma Sciences Supports University of Arizona College of Medicine – Phoenix Neurotrauma Research with Challenge Grant Award
October 25, 2021
Preclinical research to focus on sleep, inflammation and efficacy of the NTS compound NTS-104 in TBI
Track TBI Study Published in JAMA Neurology
July 19, 2021
Landmark study in mild TBI (mTBI), supported in part by a grant from NeuroTrauma Sciences, helps define CT (computed tomography) scan features associated with adverse outcomes after mTBI
